Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Feb 9, 2010

Premium

RainDance Technologies has appointed Sirshendu Roopom Banerjee to be company president and CEO.

Banerjee most recently led the Life Science Tools and Diagnostics sector at investment bank Leerink Swann, and he advised healthcare companies at McKinsey and Goldman Sachs. He also formerly worked at the Dana Farber Cancer Institute, the Whitehead Institute/MIT Human Genome Project, and at the Massachusetts General Hospital Cancer Center.


Saul Kravitz has joined CLC Bio as head of its North American consulting organization. Previously, he was director of bioinformatics software at the J. Craig Venter Institute. Before that, he was at Celera Genomics, where he helped develop algorithms and software infrastructure for high-throughput protein identification and quantitation from mass spectrometry data, and contributed to the development of Celera's whole-genome shotgun assembler.


Illumina said this week that Jack Goldstein will not stand for re-election to the company's board of directors at the firm's next annual stockholders meeting in May.


NanoString Technologies has tapped William Young to serve as executive chairman of its board of directors. Young currently is chairman of the board at Biogen Idec, a director and chairman emeritus for BayBio, and a director at Theravance. He formerly was CEO and chairman at Monogram Biosciences, and he was COO at Genentech.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.